View Profile

Pre/Non Reviewed Papers, Proceedings

Year Title Authors
1. 2010 Impact of UFT/cyclophosphamide metronomic chemotherapy and antiangiogenic drug therapy assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma
2. 2010 Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer
3. 2010 Anti-Tumor Effect of CT-322 as an Adnectin Inhibitor of Vascular Endothelial Growth Factor Receptor-2.
4. 2010 Metronomic irinotecan therapy combined with bevacizumab for effective treatment of preclinical advanced ovarian cancer: role of SDF-1 inhibition.
5. 2010 Binding properties of epidermal growth factor receptor targeted monoclonal antibodies: factors contributing to differences in toxicity profiles
6. 2010 Human tumor xenografts that acquire resistance to metronomic cyclophosphamide chemotherapy retain sensitivity to maximum tolerated cyclophosphamide doses
7. 2010 Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy
8. 2010 Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of response.
9. 2010 Cancer Stem Cells Promote Tumor Vascular Development - Response
10. 2010 Liver surgery induces an immediate mobilization of progenitor cells in liver cancer patients: A potential role for G-CSF
11. 2009 Effective treatment of advanced human melanoma metastasis in immunodeficient mice using combination metronomic chemotherapy regimens.
12. 2009 Autocrine expression of VEGF upon uptake of tumor-derived microvesicles containing oncogenic EGFR.
13. 2009 Acceleration of metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis
14. 2009 Comparative impact of trastuzumab and cyclophosphamide on HER-2 positive human breast cancer xenografts
15. 2009 Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent anti-tumor activity in preclinical human tumor xenograft models
16. 2009 Contribution of G-CSF to the acute mobilization of endothelial precursor cells by vascular disrupting agents
17. 2009 Tumor and Host-Mediated pathways of resistance and disease progression in response to antiangiogenic therapy
18. 2009 Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via VEGF and SDF1.
19. 2009 Signalling to the polarity complex controls breast cancer invasion and metastasis.
20. 2009 Cetuximab causes a dose-dependent increase in circulating transforming growth factor-a that acts as pharmacodynamic marker for optimal biologic dosing
21. 2008 A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients
22. 2008 Long term progression and therapeutic response of visceral metastatic disease non-invasively monitored in mouse urine using b-human choriogonadotropin secreting tumor cell lines.
23. 2008 Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents
24. 2008 Tumor angiogenesis
25. 2008 An eosinophil immune response characterizes the inflammatory skin disease observed in Tie-2 transgenic mice
26. 2008 Endothelial progenitor cells are cellular hubs essential for neoangiogenesis of certain aggressive adenocarcinomas and metastatic transition but not adenomas
27. 2008 Development of a preclinical model of spontaneous human melanoma CNS metastasis.
28. 2008 Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors
29. 2008 Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: A Children s Oncology Group Study
30. 2008 Antiangiogenic and anti-colorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib
31. 2008 Pharmacology of the novel anti-angiogenic peptide, ATN-161 (Ac-PHSCN-NH2): observation of a U-shaped dose response in several preclinical models of angiogenesis and tumor growth.
32. 2008 VEGF-mediated decrease in plasma sVEGFR-2 levels as a surrogate biomarker for tumor growth.
33. 2007 Effects of aging and hypoxia-inducible factor-1 activity on angiogenic cell mobilization and recovery of perfusion after lim ischemia.
34. 2007 Id1 restrains p21 expression to control endothelial progenitor cell formation.
35. 2007 Antiangiogenic strategies on defense: blocking rebound by the tumor vasculature after chemotherapy
36. 2007 Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity
37. 2007 Therapies combining a targeted antiangiogenic drug and cytotoxic or metronomic chemotherapy reduce the tumor stem-like cell fraction in glioma xenograft tumors.
38. 2007 Enhanced natural killer cell and erythropoietic activities in VEGF-A-overexpressing mice delay F-MuLV-induced erythroleukemia
39. 2007 Molecular and cellular biomarkers for angiogenesis in clinical oncology.
40. 2007 Multiple circulating pro-angiogenic factors systemically induced by sunitinib malate (SU11248) are tumor-independent and correlate with anti-tumor efficacy.
41. 2007 Microultrasound molecular imaging of vascular endothelial growth factor receptor 2 in a mouse model of tumor angiogenesis
42. 2007 Detecting vascular changes in tumor xenografts using micro-ultrasound and micro-CT following treatment with VEGFR-2 blocking antibodies
43. 2007 Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice
44. 2006 High-dose celecoxib and metronomic low-dose cyclophosphamide is an effective and safe therapy in patients with relapsed and refractory aggressive histology non–Hodgkin's lymphoma
45. 2006 Targeted anti-VEGFR-2 therapy leads to short and long term impairment of vascular function and increase in tumorn hypoxia
46. 2006 Antiangiogenic therapy: a universal chemosensitization strategy for cancer?
47. 2006 Circulating endothelial cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy
48. 2006 Low-dose metronomic cyclophosphamide and weekly tirapazamine: a well tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia
49. 2006 Strategies for delaying or treating in vivo acquired resistance to trastuzumab (Herceptin®) in human breast cancer xenografts
50. 2006 The multifaceted circulating endothelial cell in cancer: from promiscuity to surrogate marker and target identification
51. 2006 Therapy-induced acute recruitment of circulating endothelial progenitor cells to tumors.
52. 2006 On the origin and nature of elevated levels of circulating endothelial cells (CECs) after treatment with a vascular disrupting agent
53. 2006 Highly efficacious non-toxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT cyclophosphamide metronomic chemotherapy.
54. 2006 Influence of formulation vehicle on metronomic taxane chemotherapy: nanoparticle albumin-bound versus cremophor EL-based paclitaxel
55. 2005 Angiogenesis as a therapeutic target: advances and prospects
56. 2005 ras oncogene triggers upregulation of cIAP2 and XIAP in intestinal epithelial cells: EGF receptor-dependent and independent mechanisms of ras-induced transformation.
57. 2005 Circulating endothelial progenitor cells
58. 2005 Therapeutic implications of intrinsic or induced angiogenic growth factor redundancy in tumors revealed
59. 2005 Downregulation of DNA mismatch repair proteins in human and murine tumor spheroids: implications for multicellular resistance to alkylating agents
60. 2005 Metronomic low-dose chemotherapy boosts CD95-dependent antiangiogenic effect of the thrombospondin peptide ABT-510: a complementation antiangiogenic strategy
61. 2005 Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy.
62. 2005 The optimal biological dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity
63. 2005 In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower dose chemotherapy.
64. 2005 Cyclophosphamide-methotrexate metronomic chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation
65. 2005 The splenic microenvironment is a source of pro-angiogenesis/inflammatory mediators accelerating the expansion of murine erythroleukemic cells.
66. 2005 Careful decoy receptor titering is required to inhibit tumor angiogenesis while avoiding adversely altering VEGF bioavailability
67. 2005 A cyclosporine-sensitive psoriasis-like disease produced in Tie2 transgenic mice
68. 2005 Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis: implications for cellular surrogate marker analysis of antiangiogenesis.
69. 2005 Anti-vascular endothelial growth factor receptor-2 (Flk-1/KDR) antibody suppresses contact hypersensitivity
70. 2004 Versican/PG-M G3 domain promotes tumor growth and angiogenesis.
71. 2004 Radiation resistance of human melanoma analysed by retroviral insertional mutagenesis reveals a possible role for dopachrome tautomerase
72. 2004 Increased plasma VEGF as a surrogate marker for optimal biologic dosing of VEGFR-2 monoclonal antibodies.
73. 2004 Gene expression analysis of tumor spheroids reveals a role for suppressed DNA mismatch repair in multicellular resistance to alkylating agents.
74. 2004 Biomarkers, surrogate end points, and the acceleration of drug development for cancer prevention and treatment: an update prologue
75. 2004 Reanalysis of cancer drugs: old drugs, new tricks
76. 2004 Rationale for biomarkers and surrogate endpoints in mechanism-driven oncology drug development
77. 2004 Antiangiogenic basis of low-dose metronomic chemotherapy
78. 2004 A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma.
79. 2004 A comparative analysis of low dose metronomic cyclophosphamide reveals absent or low grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens.
80. 2004 Anti-adhesive antibodies targeting e-cadherin sensitize multicellular tumor spheroids to chemotherapy in vitro
81. 2003 Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells
82. 2003 A unique autophosphorylation site on Tie2/Tek mediates Dok-R phosphotyrosine binding domain binding and function
83. 2003 Selective anti-endothelial effects of protracted low-dose BAL-9504, a novel geranylgeranyl-transferase inhibitor.
84. 2003 Marked differences between vascularity and angiogenesis in childhood pilocytic and anaplastic astrocytomas
85. 2003 Thrombospondin-1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy.
86. 2003 Metronomic Therapy with Cyclophosphamide and Dexamethasone for Prostate Carcinoma.
87. 2003 Contrasting effects of VEGF gene disruption in embryonic stem cell-derived versus oncogene-induced tumors
88. 2003 Dok-R binds c-Abl and regulates Abl kinase activity and mediates cytoskeletal reorganization
89. 2002 Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug resistant human breast cancer xenograft
90. 2002 Imatinib mesylate (STI 571) reduces Bcr-Abl mediated VEGF secretion in chronic myelogenous leukemia.
91. 2002 Clinical translation of angiogenesis inhibitors.
92. 2002 Disruption of cell-cell adhsion enhances antibody-dependent cellular cytotoxicity: Implications for antibody-based therapeutics of cancer.
93. 2002 High frequency doppler ultrasound monitors the effects of antivascular therapy on tumor blood flow.
94. 2002 Protracted low-dose effects on human endothelial cell proliferation, adhesion and migration in vitro reveals a potential "antiangiogenic window" for chemotherapeutic drugs
95. 2002 Anti-tumor and anti-angiogenic effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water
96. 2002 VEGF isoform expression as a determinant of blood vessel patterning in human melanoma xenografts.
97. 2002 A role of survivin in chemoresistance of endothelial cells mediated by VEGF.
98. 2002 Effect of p53 status on tumor response to antiangiogenic therapy.
99. 2001 Induction of Anoikis and Suppression of Human Ovarian Tumor Growth In Vivo by Downregulation of Bcl-XL
100. 2001 Differentiated tumor architecture is lost in gastric cancer xenografts but maintained in spheroid culture.
101. 2001 Acquired resistance to the anti-tumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis
102. 2001 RB2/p130 gene-enhanced expression down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in vivo
103. 2001 Dok-R plays a pivotal role in angiopoietin-1-dependent cell migration through recruitment and activation of Pak
104. 2001 Heterogeneous vascular dependency of tumor cell populations.
105. 2000 Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341.
106. 2000 Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner.
107. 2000 Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity.
108. 2000 Activated ras prevents downregulation of Bcl-XL triggered by detachment from the extracellular matrix: a mechanism of ras-induced resistance to anoikis in intestinal epithelial cells
109. 2000 Tumor angiogenesis: past, present and the near future. In
110. 2000 Oncogenes and tumor angiogenesis: differential modes of VEGF upregulation in ras-transformed epithelial cells and fibroblasts
111. 2000 Tyrosinase-related protein-2 as a mediator of melanoma specific resistance to cis-diamminedichloroplatinum(II): therapeutic implications
112. 2000 High-frequency color flow imaging of the microcirculation
113. 2000 TYRP-2 mediated resistance to cis-diamminedichloroplatinum(II) in human melanoma cells is independent of tyrosinase, TYRP1 expression, and melanin content.
114. 1999 Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21WAF1/CIP1 is lost during progression of human malignant melanoma
115. 1999 Functional dissociation of anoikis-like cell death and activity of stress activated protein kinase.
116. 1999 Proteolytic switching: opposite patterns of regulation of gelatinase B and its inhibitor Timp-1 during human melanoma progression and consequences of gelatinase B overexpression.
117. 1999 Marked induction of the IAP family anti-apoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells
118. 1999 Collateral expression of pro-angiogenic and tumorigenic properties in intestinal epithelial cell variants selected for resistance to anoikis
119. 1998 E-cadherin-dependent growth suppression is mediated by the cyclin-dependent kinase inhibitor p27KIP1
120. 1998 Impact of oncogenes in tumor angiogenesis: mutant K-ras upregulation of VEGF/VPF is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells
121. 1998 Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival
122. 1998 von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids.
123. 1998 Downregulation of the pro-apoptotic protein Bak is required for the ras-induced transformation of intestinal epithelial cells.
124. 1998 Reversal of intrinsic and acquired forms of drug resistance by hyaluronidase treatment of solid tumors
125. 1998 Termination of the dormant phenotype of early stage primary human cutaneous melanoma by overexpression of vascular endothelial growth factor.
126. 1998 Overexpression of Lerk-5/Eplg5 messenger RNA: a novel marker for increased tumorigenicity and metastatic potential in human malignant melanomas
127. 1997 Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids
128. 1997 Neutralizing antibodies against EGF and ErbB-2/neu receptor tyrosine kinases down-regulate VEGF production by tumor cells in vitro and in vivo: Angiogenic implications for signal transduction therapy of solid tumors
129. 1997 Differential expression patterns of S100A2, S100A4 and S100A6 during progression of human malignant melanoma
130. 1996 Impact of the cyclin-dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents
131. 1996 Reversal of hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells
132. 1996 Multiple features of advanced melanoma recapitulated in tumorigenic variants of early stage (radial growth phase) human melanoma cell lines: evidence for a dominant phenotype.
133. 1996 Endogenous interleukin 6 can function as an in vivo growth-stimulatory factor for advanced-stage human melanoma cells
134. 1996 TGF-β mediated G1 arrest in a human melanoma cell line lacking p15INK4B: Evidence for cooperation between p21CIP1/WAF1 and p27KIP1.
135. 1996 Cyclin kinase inhibitor p21WAF1/CIP1 in malignant melanoma.
136. 1995 Interleukin 12: Newest member of the antiangiogenesis club.
137. 1995 TGFβ1 is an autocrine positive regulator of colon carcinoma U9 cells in vivo as shown by transfection of a TGF-β1 antisense expression plasmid
138. 1995 Massive programmed cell death in intestinal epithelial cells induced by three-dimensional growth conditions: suppression by mutant c-H-ras oncogene expression.
139. 1995 Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis.
140. 1995 The 92 kDa gelatinase B is expressed by advanced stage melanoma cells: Suppression by somatic cell hybridization with early stage melanoma cells.
141. 1995 Constitutive production of 92 kDa gelatinase B can be suppressed by alterations in cell shape
142. 1995 Expression of leukemia inhibitory factor (LIF) and interleukin-11 (IL-11) by human melanoma cell lines: LIF, IL-6, and IL-11 are not co-regulated.
143. 1995 The melanoma differentiation-associated gene mda-6, which encodes the cyclin-dependent kinase inhibitor p21, is differentially expressed during growth, differentiation and progression in human melanoma cells
144. 1995 Retroviral insertional mutagenesis as a stragegy for the indentificaiton of genes associated with cis-diamminedichloroplatinum (II) resistance
145. 1994 Progressive loss of sensitivity to endothelium-derived growth inhibitors expressed by human melanoma cells during disease progression.
146. 1994 Extent of vascularization as an independent prognostic indicator in thin (0.76 mm) malignant melanomas
147. 1994 Rapid acquisition of `multicellular' drug resistance after transient exposure of mammary tumor cells to alkylating agents
148. 1994 Variant sublines of early-stage human melanomas selected for tumorigenicity in nude mice express a multicytokine resistant phenotype
149. 1993 Repression of autocrine TGF-β1 and β2 in quiescent CBS colon carcinoma cells leads to progression of tumorigenic properties
150. 1993 Growth advantage (clonal dominance) of metastatically-competent tumor cell variants expressed under selective two or three dimensional tisue culture conditions.
151. 1993 Lack of influence of c-Ha-ras expression on the drug sensitivity of human bladder cancer histocultured in three-dimensions.
152. 1993 Increased resistance to oncostatin M-induced growth inhibition of human melanoma cell lines derived from advanced-stage lesions
153. 1993 Establishment and characterization of first trimester human trophoblast cells with extended lifespan
154. 1993 Acquired multicellular-mediated resistance to alkylating agents in cancer.
155. 1993 Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression
156. 1993 Responsiveness of normal/dysplastic melanocytes and melanoma cells from different lesional stages of progression to the growth inhibitory effects of TGF-β
157. 1993 Tumor cells grown as monolayers or multicellular spheroids indicate autoregulation of TGF-β gene expression is dependent on tissue architecture
158. 1992 A fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression
159. 1992 TGF-β1 as a negative growth regulator of human cancer growth in vivo revealed by transfection of an anti-sense expression vector.
160. 1992 Extensive multi-organ metastases of histologically-intact human bladder carcinoma in nude mice.
161. 1992 Structure and function of murine TIMP gene
162. 1992 Expression and functional activity of P-glycoprotein in cultured cerebral capillary endothelial cells
163. 1992 Expression of multicytokine resistance and multigrowth factor independence in advanced stage metastatic cancer: malignant melanoma as a paradigm
164. 1991 Autocrine and paracrine regulation of tissue inhibitor of metalloproteinases (TIMP), transin and urokinase gene expression in metastatic and nonmetastatic mammary carcinoma cells
165. 1991 Constitutive expression and secretion of proteases in nonmetastatic SP1 mammary carcinoma cells and its metastatic sublines
166. 1991 Fibroblast interactions with human melanoma cells affect tumor cell growth as a function of tumor progression
167. 1991 Drug-induced hypomethylation and reactivation of the asparagine synthetase gene: a new model for acquired drug resistance
168. 1991 Dominance of metastatically competent cells in primary murine breast neoplasms is necessary for distant metastatic spread
169. 1991 Transglutaminase stabilizes melanoma adhesion under laminar flow
170. 1991 Cloning and overexpression of TGF-β1 cDNA in a mammary adenocarcinoma: in vitro and in vivo effects
171. 1991 Ha-ras induction of the invasive phenotype results in up-regulation of epidermal growth factor receptors and altered responsiveness to epidermal growth factor in human papillary transitional cell carcinoma cells
172. 1991 Cytogenetic heterogeneity of genetically marked and metastatically competent "dominant" tumor cell clones
173. 1991 Reduction of TGF-beta activity abrogates growth promoting tumor cell-cell interactions in vivo.
174. 1990 Tumor cell surface β1-4-linked galactose binds to lectin(s) on microvascular endothelial cells and contributes to organ colonization
175. 1990 Cure of human melanoma lung metastases in nude mice with chronic indomethicin therapy combined with multiple rounds of 1L-2: characteristics of killer cells generated in situ
176. 1990 Overexpression of normal and mutated forms of c-Ha-ras induce orthotopic bladder invasion in a human superficial transitional cell carcinoma
177. 1990 Basement membrane invasion by first trimester human trophoblast: requirement for branched complex-type asn-linked oligosaccharides
178. 1989 Increased class I major histocompatibility antigen expression fails to alter tumor immunogenicity of a spontaneous murine carcinoma
179. 1989 Modulation by interferons of HLA antigens, high molecular weight -- melanoma associated antigen and intracellular adhesion molecule-1 expression by cultured melanoma cells with different metastatic potential
180. 1989 Enhanced tumorigenicity, melanogenesis, and metastasis of a human malignant melanoma observed after subdermal implantation in nude mice
181. 1989 Characterization of a metastasis deficient lectin-resistant human melanoma mutant.
182. 1989 Mechanisms of cellular invasiveness: A comparison of amnion invasion in vitro and metastatic behaviour in vivo
183. 1989 Possible involvement of Ca2+ mobilization and protein kinase c activation in the induction of spontaneous metastasis by mouse mammary adenocarcinoma cells.
184. 1988 Differential induction by immune interferon of the gene products of the HLA-D region on the melanoma cell line MeWo and its metastatic variant MeM 50-101
185. 1988 Genetic evidence for progressive selection and overgrowth of primary tumors by metastatic cell subpopulations
186. 1988 Highly pigmented human melanoma variant which metastasizes widely in nude mice including to skin and brain
187. 1988 Genetic tagging of tumor cells with retrovirus vectors: clonal analysis of tumor growth and metastasis in vivo.
188. 1988 Heritable high frequency modulation of antigen expression in neoplastic cells exposed to 5-aza-2' deoxycytidine or hydroxyurea: analysis and implications.
189. 1988 Isolation and characterization of spontaneous wheat germ agglutinin-resistant (WGAr) human melanoma mutants displaying remarkably different metastatic profiles in nude mice.
190. 1987 Metastatic potential of SP1 mouse mammary adenocarcinoma cells is differentially induced by activated and normal forms of c-H-ras
191. 1987 Reduced levels of DNA 5-methylcytosine in metastatic variants of the human melanoma cell line MeWo
192. 1987 Selection of metastatic variants from a non-metastatic murine tumor after treatment with 2'deoxy-5-azacytidine or hydroxyurea: implications for the mechanisms of tumor progression.
193. 1987 β1-6 branching of Asn-linked oligosaccharides is directly associated with metastasis.
194. 1987 Alteration of the tumorigenic and metastatic properties of neoplastic cells is associated with the process of calcium phosphate mediated DNA transfection
195. 1986 Periodate-oxidized adenosine induction of murine thymidine kinase: role of DNA methylation in the generation of tumor cell heterogeneity
196. 1985 Induction of thymidine kinase activity in a spontaneously enzyme-deficient murine tumor cell line by exposure in vivo to the DNA hypomethylation agent 5-Aza-2'-deoxycytidine: implications for mechanisms of tumor progression
197. 1985 Enhanced expression of class 1 MHC (Dk) gene products on immunogenic variants of a spontaneous murine carcinoma
198. 1984 5-azacytidine induction of thymidine kinase in a spontaneously enzyme deficient murine tumor line
199. 1984 Single-step selection of unique human melanoma variants displaying unusually aggressive metastatic behavior in nude athymic mice
200. 1984 Adoptive immune therapy of mice bearing poorly immunogenic metastases using T lymphocytes stimulated in vitro against highly immunogenic mutant sublines.
201. 1984 Metastatic properties of distinct phenotypic classes of lectin-resistant mutants isolated from the murine MDAY-D2 cell line
202. 1984 Characterization of in vitro immunoselected variants from a highly metastatic murine tumor for alterations in malignant behavior in vivo.
203. 1984 Alterations in sensitivity to nonspecific cell-mediated lysis associated with tumor progression: characterization of activated macrophage- and natural killer cell-resistant tumor variants.
204. 1984 Selection of strongly immunogenic "tum-" variants from tumors at high frequency using 5-azacytidine
205. 1984 A model of human cancer metastasis: extensive spontaneous and artificial metastasis of a human pigmented and derived variant sublines in nude mice
206. 1983 Spontaneous fusion in vivo between normal host and tumor cells: possible contribution to tumor progression and metastasis studied with a lectin-resistant mutant tumor.
207. 1983 Genotypic and phenotypic evolution of a murine tumor during its progression in vivo toward metastasis
208. 1983 Mutagen treatment as a means for selecting immunogenic variants from otherwise poorly immunogenic malignant murine tumors.
209. 1982 A new method for the preparation of solid-phase immunoabsorbents.
210. 1982 Abrogation of the in vitro generation of the cytotoxic T cell response to a murine tumor: the role of suppressor cells
211. 1982 A comparative analysis of cell surface markers on murine NK cells and CTL, target-effector conjugates
212. 1981 Immunoselection in vitro of a highly metastatic tumor
213. 1981 EA rosettes using IgG monoclonal antibody-coated erythrocytes. Degree of formation correlates with the amount of antibody on the erythrocytes
214. 1981 An examination of tumor antigen loss in spontaneous metastases
215. 1981 Apparent reversion of stable in vitro genetic markers detected in tumour cells from spontaneous metastases
216. 1981 Generation of highly metastatic tumors in DBA/2 mice. Oncogenicity of A strain tumor cells.
217. 1981 Demonstration of a correlation between tumor cell H-2 antigen content, immunogenicity, and tumorigenicity using lectin-resistant tumor variants.
218. 1981 Selective NK resistance in a clone of YAC lymphoma cells
219. 1981 Induction of a malignant lymphoreticular cell line which displays spontaneous killer cell activity.
220. 1981 Characterization of a deficiency in fucose metabolism in lectin-resistant variants of a murine tumor showing altered tumorigenic and metastatic capacities in vivo
221. 1981 Membrane-associated alterations detected in poorly tumorigenic lectin-resistant variant sublines of a highly malignant and metastatic murine tumor.
222. 1980 Carcinogenicity of tumor cell populations: origin of a putative H-2 isoantigenic loss variant tumor.
223. 1980 Increased sensitivity of rosetting assay for Fc receptors obtained by using non-hemagglutinating monoclonal antibodies
224. 1979 Immunological studies on membrane mutants of a highly metastatic murine tumor.
225. 1979 Immune-mediated arrest and reversal of established visceral metastases in athymic mice.
226. 1979 Adult and pre-adult thymectomy of mice: contrasting effects on immune-responsiveness, and on numbers of mitogen-responsive and Thy-1 lymphocytes
227. 1978 A simple and convenient method for producing anti-activated lymphocyte allo-antisera which does not require prior absorption
228. 1978 Induction of a tumor with greatly increased metastatic growth potential by injection of cells from a low-metastatic H-2 heterozygous tumor cell line into an H-2 incompatible parental strain
229. 1977 Analysis of established human carcinoma cell lines for lymphoreticular associated receptors including Fc receptors
230. 1977 Surface antigen changes accompanying lymphocyte activation: Selective reactivity of certain anti-H-2 sera with activated lymphocytes of unrelated H-2 haplotype
231. 1976 Resistance of activated macrophages to H-2 antibody-mediated cytotoxicity and Fc rosette inhibition
232. 1976 Anomalous reactivity of anti-T sera on spleen cells from T-cell- deprived mice and on mitogen-stimulated nude mice spleen cells
233. 1976 Fc receptor-bearing cells as a reliable marker for quantitation of host lymphoreticular infiltration of progressively growing solid tumors
234. 1976 Rapid adsorption of a fetal calf serum component by mammalian cells in culture: a potential source of artifacts in studies of antisera in cell-specific antigens
235. 1976 An assessment of intratumor phagocytic and surface marker-bearing cells in a series of autochthonous and early passages chemically induces sarcomas
236. 1976 Enumeration of polyclonal mitogen-responsive cells in different lymphoid tissues of the mouse
237. 1975 Lymphocytes-erythrocytes (L.E.) rosettes as indicators of the heterogeneity of lymphocytes in a variety of mammalian species
238. 1975 Origin and partial characterization of Fc receptor-bearing cells found within experimental carcinomas and sarcomas
239. 1975 Ultrastructural and serological studies on the resistance of activated B cells to the cytotoxic effects of anti-Ig serum: patch and cap formation of surface immunoglobulin on mitotic B lymphocytes.
240. 1974 Rosette formation by a mouse fibroblast cell line
241. 1974 Resistance of mitotic B lymphocytes to the cytotoxic effects of anti-Ig serum.
242. 1974 Assessment of mitotic thymus-derived lymphocytes by their sensitivity to the cytotoxic effects of anti-θ serum
243. 1972 Classification of thymus-derived and marrow-derived lymphocytes by demonstration of their antigen-binding characteristics
244. 1972 Enhanced immune responsiveness to a thymus-independent antigen early after adult thymectomy: evidence for short-lived inhibitory thymus-derived cells
245. 1971 Further studies on antigenic competition. III. A model to account for the phenomenon based on a deficiency of cell-to-cell interaction in immune lymphoid cell populations
246. 1971 Variable effects of anti-lymphocyte serum on humoral antibody formation: role of thymus-dependency of antigen
247. 1971 New hypothesis of antigenic competition based on cell interactions in the immune response.
248. 1971 Further studies on competition of antigens. I. Variation of immunosuppression induced by alterations of dosage, route of injection, nature of antigen and immunological status of host.

About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.